Bristol Pravachol New Rx Up 22% Since Baycol Withdrawal, Company Says

01 Oct 2001

• By The Pink Sheet

New prescriptions for Bristol-Myers Squibb's Pravachol have increased 22% since the withdrawal of Bayer's Baycol, Bristol CEO Peter Dolan told a Bear Stearns healthcare conference call Sept. 25.

Bristol Pravachol New Rx Up 22% Since Baycol Withdrawal, Company Says

More from Archive

More from Pink Sheet